OncoAID

The rapid development of targeted therapies has transformed oncology by advancing precision medicine that focuses on specific molecular drivers of cancer, improving therapeutic efficacy while minimizing side effects. Since the approval of the first targeted therapies by the U.S. Food and Drug Administration (FDA), over 100 agents have been authorized by 2024, marking significant progress in understanding cancer biology and its molecular underpinnings. Databases like PHARMGKB, DrugBank and TTD have long been essential tools for clinicians; however, with the growing complexity of treatment options and the increasing integration of artificial intelligence (AI) in clinical decision-making, there is a pressing need for more comprehensive and accessible platforms. The OncoAID database addresses this demand by cataloguing FDA-approved anti-cancer therapies, including both monotherapies and combination treatments, with an emphasis on simplicity and clarity. It features AI-generated summaries and link to additional resources, enhancing the utility of the database for clinicians and researchers alike. A standout feature of the OncoAID database is its global scope, incorporating regulatory approval data from international authorities such as the FDA, EMA, and WHO. With an intuitive, user-friendly interface, the database supports personalized treatment planning and the application of machine learning in precision oncology. By offering detailed treatment profiles and encouraging novel drug combination explorations, the OncoAID database hold the potentia to play a key role in advancing cancer therapy innovation. The database is continuously updated and can be accessed at https://cancerdrugdb.onrender.com/, ensuring its relevance as a crucial resource in both clinical and research settings.